A Phase I Randomised, Single-blind, Placebo-controlled, and Sequential Group Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4144 Following Single and Multiple Ascending Doses Via Oral Administration to Healthy Participants
Latest Information Update: 17 Dec 2024
At a glance
- Drugs AZD 4144 (Primary)
- Indications Unspecified
- Focus Adverse reactions; First in man
- Sponsors AstraZeneca
Most Recent Events
- 13 Dec 2024 Status changed from recruiting to completed.
- 30 Oct 2024 Planned End Date changed from 13 Nov 2024 to 4 Dec 2024.
- 30 Oct 2024 Planned primary completion date changed from 13 Nov 2024 to 4 Dec 2024.